|
🦁
|
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
7 auth.
S. Jarrett,
G. Cunnane,
P. Conaghan,
S. Bingham,
M. Buch,
M. Quinn,
...
P. Emery
|
7 |
2003 |
7
🦁
|
|
🐜
|
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study
10 auth.
H. Marzo-Ortega,
D. McGonagle,
S. Jarrett,
G. Haugeberg,
E. Hensor,
P. O'connor,
...
A. Tan,
P. Conaghan,
A. Greenstein,
P. Emery
|
7 |
2005 |
7
🐜
|
|
🐜
|
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
17 auth.
V. Bejarano,
M. Quinn,
P. Conaghan,
R. Reece,
A. Keenan,
D. Walker,
A. Gough,
Michael J. Green,
D. McGonagle,
A. Adebajo,
...
S. Jarrett,
S. Doherty,
L. Hordon,
R. Melsom,
K. Unnebrink,
H. Kupper,
P. Emery
|
7 |
2008 |
7
🐜
|
|
🦁
|
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.
8 auth.
S. Jarrett,
P. Conaghan,
V. Sloan,
P. Papanastasiou,
C. Ortmann,
P. O'connor,
...
A. Grainger,
P. Emery
|
7 |
2006 |
7
🦁
|
|
🐜
|
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
73 auth.
F. Carmona,
S. Mackie,
Jose-Ezequiel Martin,
John C. Taylor,
A. Vaglio,
S. Eyre,
L. Bossini‐Castillo,
S. Castañeda,
M. Cid,
J. Hernández-Rodríguez,
S. Prieto-González,
R. Solans,
Marc Ramentol-sintas,
M. González-Escribano,
L. Ortiz-Fernández,
...
I. Morado,
J. Narváez,
J. Miranda-filloy,
L. Beretta,
C. Lunardi,
M. Cimmino,
D. Gianfreda,
D. Santilli,
G. Ramirez,
A. Soriano,
F. Muratore,
G. Pazzola,
O. Addimanda,
C. Wijmenga,
T. Witte,
J. Schirmer,
F. Moosig,
V. Schönau,
A. Franke,
Ø. Palm,
Ø. Molberg,
A. Diamantopoulos,
S. Carette,
D. Cuthbertson,
Lindsy J. Forbess,
G. Hoffman,
N. Khalidi,
C. Koening,
C. Langford,
Carol A. McAlear,
L. Moreland,
P. Monach,
C. Pagnoux,
P. Seo,
R. Spiera,
A. Sreih,
K. Warrington,
S. Ytterberg,
P. Gregersen,
C. Pease,
A. Gough,
Michael Green,
L. Hordon,
S. Jarrett,
R. Watts,
Sarah Levy,
Y. Patel,
S. Kamath,
B. Dasgupta,
Jane Worthington,
B. Koeleman,
P. D. de Bakker,
J. Barrett,
C. Salvarani,
P. Merkel,
M. González-Gay,
A. Morgan,
Javier Martín
|
7 |
2015 |
7
🐜
|
|
🦁
|
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib
10 auth.
S. Jarrett,
F. Sivera,
L. Cawkwell,
H. Marzo-Ortega,
D. McGonagle,
E. Hensor,
...
L. Coates,
P. O'connor,
P. Conaghan,
P. Emery
|
6 |
2008 |
6
🦁
|
|
🐜
|
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
8 auth.
Benazier Saleem,
S. Mackie,
M. Quinn,
S. Nizam,
E. Hensor,
S. Jarrett,
...
P. Conaghan,
P. Emery
|
6 |
2008 |
6
🐜
|
|
🐜
|
Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.
7 auth.
S. Harrison,
D. McGonagle,
S. Nizam,
S. Jarrett,
J. V. D. van der Hilst,
M. McDermott,
...
S. Savic
|
5 |
2016 |
5
🐜
|
|
🐜
|
Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
13 auth.
S. Mackie,
John C. Taylor,
L. Haroon-Rashid,
Stephen G. Martin,
B. Dasgupta,
A. Gough,
Michael Green,
L. Hordon,
S. Jarrett,
C. Pease,
...
J. Barrett,
R. Watts,
A. Morgan
|
5 |
2015 |
5
🐜
|
|
🐜
|
Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors.
11 auth.
S. Mackie,
B. Dasgupta,
L. Hordon,
A. Gough,
Michael Green,
J. Hollywood,
...
Shouma Dutta,
V. Bejarano,
S. Jarrett,
A. Morgan,
C. Pease
|
5 |
2011 |
5
🐜
|
